☰

Byondis B.V.

Reading R&D and GMP data as one continuous chain

Industry
Biopharmaceuticals
Headquarters
Nijmegen, Netherlands
Public information as of
May 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Byondis B.V.'s published strategy and is not endorsed by, or produced in cooperation with, Byondis B.V.. Company website

Strategic priorities

Byondis is a Dutch biopharmaceutical company developing antibody-drug conjugates (ADCs) on a fully integrated Nijmegen campus that spans lead finding, antibody engineering, conjugation chemistry and GMP manufacturing on a single 73,000 square metre site. In December 2025 the company announced a strategic transformation that halved headcount from roughly 400 to about 200 employees, redirected the business toward out-licensing its proprietary ADC platforms (ByonGuard, ByonBoost, Antifolate), and appointed Christoph Korpus, formerly of Merck KGaA, as CEO from April 2026.

The operational priority is recovering from the May 2023 FDA Complete Response Letter for [vic-]trastuzumab duocarmazine, in which the regulator requested additional information beyond the current evaluation period, a signal that CMC documentation and end-to-end traceability were not yet approvable. The 2024 Annual Report records only 0.8 million euros of software assets and 216 thousand euros of software under construction for an organisation of this scope, which points to chronic under-investment in the LIMS, ELN and MES layers that connect laboratory output to manufacturing output.

Manufacturing capacity sits in two adjacent plants: dual 2,000 litre single-use bioreactors for monoclonal antibody production and a high-potency clean room suite for ADC conjugation. The 2023 raw-material write-down — nearly the entire value of materials redirected from commercial to R&D use — signals that supply-chain forecasting and process prediction are still catching up with the manufacturing complexity ADCs introduce.

Bringing 200 people through a campus designed for 400 only works if the digital layer absorbs the manual work that left with them. That means telemetry that is continuous rather than sampled, lab data that flows into GMP by data rather than by transcription, and an audit trail that holds together from sensor to submission.

Challenges we see

  • Compliance Regulatory

    Rebuilding CMC documentation for future submissions

    The FDA Complete Response Letter issued in May 2023 for [vic-]trastuzumab duocarmazine requested additional information beyond the current evaluation period. The Byondis EMA submission had been validated, and the company also operates under MEB oversight in the Netherlands for its Nijmegen site.

    Where dossiers depend on records reconstructed from disconnected systems, the gap between what regulators want and what is readily assembled is the bottleneck, and the way to close that gap is to generate the evidence continuously during the work rather than compile it at submission.

  • Digital Integration

    Linking R&D output to GMP execution across one campus

    The 2024 Annual Report records 0.8 million euros of software assets and 216 thousand euros of software under construction, against a 2,000 m² R&D footprint and dual 2,000L GMP plants. Byondis cites connecting discovery to commercial supply as a strategic pillar.

    Where research and manufacturing live in separate systems on the same site, the handover between them is a manual step that has to be repeated for every batch and every deviation, and a single shared ontology is what turns the handover from a translation exercise into a data flow.

  • Operations Manufacturing

    Operating a 2,000L ADC plant with a team sized for half its workload

    Following the December 2025 strategic transformation, headcount was reduced from approximately 400 to 200 while the dual 2,000L bioreactor mAb plant and the high-potency ADC conjugation suite were preserved on the same 73,000 m² footprint.

    When manual oversight falls out of reach, the next batch is the one where you learn it was out of reach, so the practical question is what can be observed and acted on automatically while the team focuses on judgement calls rather than routine checks.

  • Operations Manufacturing

    Holding drug-to-antibody ratio steady at production scale

    ADC conjugation depends on stoichiometric control of the drug-to-antibody ratio (DAR). The 2023 Annual Report records a near-total write-down of raw materials redirected from commercial to R&D use, indicating that forecasting and process prediction lagged behind actual plant demand.

    When material use and process parameters are not visible together in real time, the same kind of drift that hurts the conjugation yield also distorts planning, so connecting the two views is what turns forecasting from a guess into a calculation.

  • Compliance Cybersecurity

    Protecting proprietary linker chemistry across a converged campus network

    The 2024 Annual Report explicitly flags cybersecurity and the protection of patent information as strategic risks. The Nijmegen campus combines high-speed office Wi-Fi with legacy OT systems from multiple vendors across a single network, and the company's value rests on the exclusivity of its linker-drug platforms (ByonZine, ByonGuard).

    Where the boundary between office and plant networks is permeable, the platforms themselves become the soft target, so segmenting that boundary is what lets partner due-diligence reviews proceed without exposing the things they are reviewing.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Streaming bioreactor and conjugation telemetry into one view

    The dual 2,000L single-use bioreactors and the high-potency ADC conjugation suite produce sparse, vendor-locked telemetry that operators see only through legacy SCADA screens and post-hoc spreadsheets, rather than as a continuous picture of the running batch.

    A process-intelligence layer with P&ID-aligned (Piping and Instrumentation Diagram) dashboards and overlays against ideal historical runs lets the leaner team see deviation in seconds rather than days, so the ADC batch value is protected by the visibility itself.

    • Byondis 2024 Annual Report
    • Byondis Announces Strategic Transformation, press release, December 2025

  2. Connecting lab instruments to a single ALCOA+ data chain

    Research data from the 2,000 m² discovery labs moves into the GMP plants through manual transcription across instruments from multiple vendors, producing the kind of traceability gap the 2023 FDA CRL signalised.

    An OPC UA-based (Open Platform Communications Unified Architecture) vendor-neutral integration spine and an ontology-driven data platform let sensor output and laboratory records share one ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) audit trail from sensor to submission, which is the property future BLA and MAA filings will be checked against.

    • FDA Complete Response Letter for [vic-]trastuzumab duocarmazine, May 2023
    • Byondis 2024 Annual Report

  3. Installing a non-invasive vision layer over the 2,000L bioreactors

    A team of roughly 200 cannot maintain continuous visual checks of foam, level and clarity events in the 2,000L plant that can cause filter blockage, contamination and batch loss, and the consequence of a missed event compounds across an overnight shift.

    An external-camera vision system with closed-loop antifoam dosing extends effective coverage to 168 hours per week without adding headcount, while reducing antifoam overuse and the contamination risk it introduces.

    • Byondis 2024 Annual Report
    • Byondis Announces Strategic Transformation, December 2025

  4. Eliminating single points of failure in the R&D IT estate

    The campus relies on isolated Industrial PCs, locally installed lab software and unsegmented networks, a topology that cannot survive partner due-diligence scrutiny or a ransomware event without halting the science that depends on it.

    Migration to a high-availability containerised cluster with strict VLAN segmentation (Virtual Local Area Network) and Zero-Trust identity removes the single points of failure and produces the audit posture partner-led data rooms expect to see.

    • Byondis 2024 Annual Report

  5. Replacing paper QC logs with a barcode-driven execution system

    QC pH, balance, conductivity and release tests are still anchored in paper logbooks and instrument-local memory, a working pattern that an FDA reviewer is likely to compare against the ALCOA+ expectations that informed the 2023 CRL.

    A Laboratory Execution System with barcode-driven capture, harmonised workflows and SAP or LIMS integration makes every batch release audit-ready by default and removes the manual transcription that has been the source of prior findings.

    • FDA Complete Response Letter for [vic-]trastuzumab duocarmazine, May 2023
    • Byondis 2024 Annual Report

What we'd propose

  • Digital Lab

    One data spine for the R&D and GMP sides of the Nijmegen campus

    A vendor-neutral integration program that connects heterogeneous laboratory and plant instruments across the 2,000 m² R&D space and the dual 2,000L mAb and ADC plants into a single OPC UA-based data layer, with segmented IT and OT (Operational Technology) networking so research data reaches enterprise systems without exposing plant systems to lateral movement.

    • Vendor-neutral instrument integration

      Drivers for every lab and plant class

      Custom OPC UA drivers and connectors ingest data from Roche, Hamilton and Beckman-class analysers and from single-use bioreactor sensors into a central historian, so legacy instruments publish their values in a documented form rather than through screen scraping or print logs.

    • VLAN-segmented IT/OT network

      Office and plant on different tracks

      Reconfigure the campus connectivity layer with strict VLAN segmentation and secure OT gateways so research data flows to IT and the cloud without exposing OT systems to lateral threats, which is the property partner due-diligence reviews are checking for.

    • Day-1 validation sprint

      Connected plant on Monday morning

      Run a parallel-stream commissioning team that validates sensor-to-dashboard data integrity in real time, so scientists return from a Friday handover to a fully connected plant on Monday rather than to a staged rollout that runs for months.

    • End-to-end traceability from sensor to submission, which is the property future BLA and MAA reviews will be measured against.
    • One connectivity pattern reusable across the 2,000 m² R&D space, the 2,000L mAb plant and the ADC clean room.
    • Partner due-diligence reviews meet a single data architecture rather than a patchwork of point-to-point interfaces.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Real-time process intelligence for the ADC conjugation suite

    A process-intelligence layer with P&ID-aligned dashboards and overlays against ideal historical runs that turns bioreactor and conjugation telemetry into a continuous view the leaner team can act on while a batch is still running.

    • P&ID-aligned dashboards

      Visual replicas of the suites

      Build the digital twin of each 2,000L unit and of the ADC clean room so the on-screen layout mirrors the physical piping and instrumentation, cutting operator cognitive load when responding to an event.

    • Golden-batch overlay

      Live comparison with the best run on file

      Overlay current run telemetry against curated historical profiles so deviations in DAR, VCD (viable cell density) or pH trigger immediate corrective action rather than retrospective troubleshooting the next morning.

    • Severity-tiered alarm management

      Alerts that mean what they say

      Re-tier alarms by biological and process criticality so the smaller team responds only to events that genuinely need a person, which reduces alarm fatigue and the desensitisation that comes with it.

    • Deviations surface while the batch is running, so corrective action still has time to land.
    • The same telemetry serves manufacturing, quality and engineering rather than three separate exports.
    • Forecasting can be done from the same data, addressing the 2023 raw-material write-down signal.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Non-invasive vision system for the 2,000L bioreactors

    An external-camera vision system with closed-loop antifoam dosing that extends effective oversight of foam, level and clarity events in the 2,000L plant to 168 hours per week without adding headcount.

    • External-camera vision sensing

      No probes in the sterile path

      Mount external cameras with image-processing models that detect foam level, density and clarity in real time, without contacting the sterile medium or modifying the reactor hardware, which keeps the existing single-use flow intact.

    • Adaptive antifoam dosing

      Right amount, only when needed

      Translate vision signals into pulsed pump activation that handles both slow-rising foam and flash events, reducing antifoam chemical consumption and protecting cell-growth kinetics from overdose.

    • Continuous unattended coverage

      Lights-out without lights-out risk

      Extend the lean team's effective coverage overnight and across weekends, with the vision system logging every event for after-hours review rather than relying on a person being on the floor.

    • Continuous oversight of every high-cost ADC batch without a proportional headcount cost.
    • Reduced antifoam use and the contamination risk that comes with it.
    • An immediately observable pilot that can be expanded to the conjugation suite once the pattern is proven.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Zero-Trust high-availability cluster for the R&D IT estate

    Migration of the Nijmegen lab-IT estate from isolated Industrial PCs to a high-availability containerised cluster with Zero-Trust identity and Infrastructure-as-Code governance, so partner due diligence meets a documented architecture rather than a patchwork of single points of failure.

    • Containerised high-availability cluster

      Workloads that move when a host fails

      Encapsulate lab applications into containers with workload migration between nodes, so a host failure does not halt the data room or the experiment that depends on it, and so outages stop being a science-stopping event.

    • Zero-Trust identity layer

      Verify every connection, every time

      Replace perimeter trust with identity-based access controls so proprietary ByonGuard, ByonBoost and ByonZine intellectual property cannot be exfiltrated via a compromised credential or lateral movement from the office network.

    • Infrastructure-as-Code template

      Reproducible by default

      Codify the cluster blueprint so any future second-site or partner-shared environment follows the identical hardened configuration without bespoke build effort, and so the configuration itself is auditable as code.

    • Core intellectual property is protected by the architecture, not by policy alone.
    • Partner due-diligence data rooms stay open through events that would otherwise halt science.
    • The same blueprint travels to the next site or the next partner environment without bespoke rebuild.

    We've done this before

    See how we do Enterprise AI
  • Agents

    GxP-ready Laboratory Execution System for QC and release

    A Laboratory Execution System design and phased rollout that replaces paper logbooks and instrument-local memory with a single ALCOA+ compliant orchestration layer across quality control, so every batch release is audit-ready by default rather than reconstructed for review.

    • Harmonised digital workflows

      One SOP across the QC bench

      Design unified digital procedures for pH, balance and conductivity testing that enforce a single standard across the QC operation, eliminating the operator-to-operator variability that regulators typically flag during inspections.

    • Barcode-driven capture

      Results written by the instrument

      Integrate barcode scanning so analyst, instrument and method are validated in real time and every result writes directly to LIMS or LES, removing the transcription step that has historically been the source of data-integrity findings.

    • Pre-submission completeness check

      Documents arrive review-ready

      Deploy a narrow check that reviews a draft against its template and the site's own checklist before the document enters the human review queue, so reviewers spend their time on the technical judgement inside the document rather than on assembling it.

    • Batch releases rest on a continuous audit trail rather than on records reconstructed for review.
    • The next BLA or MAA filing draws on data the system produced, not data the team compiled.
    • Reviewers' time is spent on judgement rather than on assembly.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Byondis B.V.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 30 → 85
The 2024 Annual Report records 0.8 million euros of software assets and 216 thousand euros under construction for a fully integrated biopharma campus, and connecting instruments across the R&D and GMP sides will require a documented integration spine rather than more point-to-point interfaces.
Lab digitalization 35 → 85
Discovery labs across 2,000 m² still depend on Excel and paper for many captures, and the post-transformation headcount makes continuous capture a working necessity rather than a future ambition.
Process analytics 25 → 80
DAR and conjugation analytics remain retrospective, and the 2023 raw-material write-down indicates that the supply-side view of process performance has not yet been connected to the production-side view.
Cybersecurity posture 40 → 90
The 2024 Annual Report explicitly names cybersecurity and patent protection as strategic risks, and the converged campus network will need documented segmentation and Zero-Trust identity before partner due-diligence reviews are routine.
Regulatory data integrity 30 → 90
The 2023 FDA Complete Response Letter is the reference point, and audit-ready evidence at submission rather than reconstructed evidence afterwards is the working bar that has to be met across every CMC deliverable.
Predictive operations 20 → 70
No public evidence of production AI/ML beyond pilot scope today, but the leaner operating model makes predictive monitoring of the 2,000L bioreactors and the ADC suite a near-term operational priority rather than a research project.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of May 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Byondis B.V., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].